@article{Kostaras2018-lk,
title = {Vaccination against HPV virus: a systematic review of economic
evaluation studies for developed countries},
author = {Dimitris Kostaras and Eleftheria Karampli and Kostas Athanasakis},
year = {2018},
date = {2018-12-01},
journal = {Expert Rev Pharmacoecon Outcomes Res},
volume = {19},
number = {2},
pages = {147--158},
address = {England},
abstract = {INTRODUCTION: During the last years, a significant number
economic evaluations of HPV vaccination has been published. Given
that cost-effectiveness constitutes an essential part of
decision-making with regards to the reimbursement of a health
technology, the purpose of this study is to provide a supportive
tool to decision-makers regarding the economic efficiency of the
introduction of HPV vaccination to national immunization
programs. AREAS COVERED: The PubMed database was searched in
order to identify cost-effectiveness studies for HPV vaccination.
A total of 42 articles were finally retrieved. All retrieved
cost-effectiveness ratios (ICERs) were converted in the same
currency unit (I$) and then inflated to the same year (2015) in
order to facilitate cross-country comparisons. RESULTS: Overall,
vaccination against HPV 6,11,16,18 types appears to have a ICER
with mean value of I$25132/QALY, whereas the mean ICER of
vaccination against oncogenic HPV 16,18 types is estimated at
I$38,253/QALY. EXPERT COMMENTARY: HPV vaccination would be a
cost-effective intervention in the setting of high-income
countries and could reduce the incidence of HPV-related diseases.},
keywords = {HPV prevention; cost-effectiveness; cost-utility; human papillomavirus; vaccination; vaccines},
pubstate = {published},
tppubtype = {article}
}
INTRODUCTION: During the last years, a significant number
economic evaluations of HPV vaccination has been published. Given
that cost-effectiveness constitutes an essential part of
decision-making with regards to the reimbursement of a health
technology, the purpose of this study is to provide a supportive
tool to decision-makers regarding the economic efficiency of the
introduction of HPV vaccination to national immunization
programs. AREAS COVERED: The PubMed database was searched in
order to identify cost-effectiveness studies for HPV vaccination.
A total of 42 articles were finally retrieved. All retrieved
cost-effectiveness ratios (ICERs) were converted in the same
currency unit (I$) and then inflated to the same year (2015) in
order to facilitate cross-country comparisons. RESULTS: Overall,
vaccination against HPV 6,11,16,18 types appears to have a ICER
with mean value of I$25132/QALY, whereas the mean ICER of
vaccination against oncogenic HPV 16,18 types is estimated at
I$38,253/QALY. EXPERT COMMENTARY: HPV vaccination would be a
cost-effective intervention in the setting of high-income
countries and could reduce the incidence of HPV-related diseases.